Does the media prefer BCRX or ABVX?

In the previous week, BioCryst Pharmaceuticals had 14 more articles in the media than Abivax. MarketBeat recorded 18 mentions for BioCryst Pharmaceuticals and 4 mentions for Abivax. Abivax's average media sentiment score of 1.55 beat BioCryst Pharmaceuticals' score of 0.55 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 3 Very Positive mention(s) 7 Positive mention(s) 1 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer KYMR or BCRX?

In the previous week, BioCryst Pharmaceuticals had 14 more articles in the media than Kymera Therapeutics. MarketBeat recorded 18 mentions for BioCryst Pharmaceuticals and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.95 beat BioCryst Pharmaceuticals' score of 0.55 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 3 Very Positive mention(s) 7 Positive mention(s) 1 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IONS or BCRX?

In the previous week, Ionis Pharmaceuticals had 9 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 27 mentions for Ionis Pharmaceuticals and 18 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.55 beat Ionis Pharmaceuticals' score of 0.34 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 4 Very Positive mention(s) 8 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral BioCryst Pharmaceuticals 3 Very Positive mention(s) 7 Positive mention(s) 1 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive

BioCryst Pharmaceuticals (BCRX) Competitors

$8.12 -0.17 (-2.05%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$8.14 +0.02 (+0.20%)

As of 09/11/2026 07:53 PM Eastern

Compare

BCRX vs. ABVX, PRAX, KYMR, IONS, and PTGX

Should you buy BioCryst Pharmaceuticals stock or one of its competitors? BioCryst Pharmaceuticals's main competitors and comparable companies include Abivax (ABVX), Praxis Precision Medicines (PRAX), Kymera Therapeutics (KYMR), Ionis Pharmaceuticals (IONS), and Protagonist Therapeutics (PTGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioCryst Pharmaceuticals compare to Abivax?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Abivax (NASDAQ:ABVX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, BioCryst Pharmaceuticals had 14 more articles in the media than Abivax. MarketBeat recorded 18 mentions for BioCryst Pharmaceuticals and 4 mentions for Abivax. Abivax's average media sentiment score of 1.55 beat BioCryst Pharmaceuticals' score of 0.55 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	3 Very Positive mention(s)	7 Positive mention(s)	1 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

BioCryst Pharmaceuticals has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.37	$263.86M	-$1.50	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

BioCryst Pharmaceuticals currently has a consensus target price of $20.40, suggesting a potential upside of 151.23%. Abivax has a consensus target price of $156.38, suggesting a potential upside of 31.81%. Given BioCryst Pharmaceuticals' higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

BioCryst Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, Abivax has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Abivax has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -40.90%. BioCryst Pharmaceuticals' return on equity of -86.89% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%
Abivax	N/A	-99.02%	-70.26%

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

BioCryst Pharmaceuticals beats Abivax on 10 of the 16 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

In the previous week, BioCryst Pharmaceuticals had 12 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 18 mentions for BioCryst Pharmaceuticals and 6 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.41 beat BioCryst Pharmaceuticals' score of 0.55 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	3 Very Positive mention(s)	7 Positive mention(s)	1 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCryst Pharmaceuticals has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	N/A	N/A	-$303.27M	-$12.93	N/A
BioCryst Pharmaceuticals	$874.84M	2.37	$263.86M	-$1.50	N/A

Praxis Precision Medicines has a beta of 2.76, suggesting that its share price is 176% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Praxis Precision Medicines has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -40.90%. Praxis Precision Medicines' return on equity of -34.15% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

Praxis Precision Medicines currently has a consensus price target of $585.95, suggesting a potential upside of 75.13%. BioCryst Pharmaceuticals has a consensus price target of $20.40, suggesting a potential upside of 151.23%. Given BioCryst Pharmaceuticals' higher probable upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.95
BioCryst Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

Summary

BioCryst Pharmaceuticals beats Praxis Precision Medicines on 9 of the 16 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

BioCryst Pharmaceuticals has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$105M	91.04	-$311.35M	-$3.24	N/A
BioCryst Pharmaceuticals	$874.84M	2.37	$263.86M	-$1.50	N/A

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

BioCryst Pharmaceuticals has a net margin of -40.90% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

Kymera Therapeutics currently has a consensus price target of $130.83, indicating a potential upside of 13.81%. BioCryst Pharmaceuticals has a consensus price target of $20.40, indicating a potential upside of 151.23%. Given BioCryst Pharmaceuticals' higher probable upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.88
BioCryst Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

Kymera Therapeutics has a beta of 1.96, meaning that its stock price is 96% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market.

In the previous week, BioCryst Pharmaceuticals had 14 more articles in the media than Kymera Therapeutics. MarketBeat recorded 18 mentions for BioCryst Pharmaceuticals and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.95 beat BioCryst Pharmaceuticals' score of 0.55 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	3 Very Positive mention(s)	7 Positive mention(s)	1 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioCryst Pharmaceuticals beats Kymera Therapeutics on 9 of the 17 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 1.8% of Ionis Pharmaceuticals shares are held by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BioCryst Pharmaceuticals has lower revenue, but higher earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	9.54	-$381.39M	-$3.46	N/A
BioCryst Pharmaceuticals	$874.84M	2.37	$263.86M	-$1.50	N/A

BioCryst Pharmaceuticals has a net margin of -40.90% compared to Ionis Pharmaceuticals' net margin of -64.76%. BioCryst Pharmaceuticals' return on equity of -86.89% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

In the previous week, Ionis Pharmaceuticals had 9 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 27 mentions for Ionis Pharmaceuticals and 18 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.55 beat Ionis Pharmaceuticals' score of 0.34 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	4 Very Positive mention(s)	8 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioCryst Pharmaceuticals	3 Very Positive mention(s)	7 Positive mention(s)	1 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive

Ionis Pharmaceuticals currently has a consensus price target of $91.25, indicating a potential upside of 68.33%. BioCryst Pharmaceuticals has a consensus price target of $20.40, indicating a potential upside of 151.23%. Given BioCryst Pharmaceuticals' higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Ionis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73
BioCryst Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

Ionis Pharmaceuticals has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

Summary

BioCryst Pharmaceuticals beats Ionis Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Protagonist Therapeutics?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

BioCryst Pharmaceuticals has higher revenue and earnings than Protagonist Therapeutics. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.37	$263.86M	-$1.50	N/A
Protagonist Therapeutics	$46.02M	208.36	-$130.15M	$1.03	143.86

BioCryst Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market.

Protagonist Therapeutics has a net margin of 29.40% compared to BioCryst Pharmaceuticals' net margin of -40.90%. Protagonist Therapeutics' return on equity of 12.03% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%
Protagonist Therapeutics	29.40%	12.03%	11.23%

BioCryst Pharmaceuticals currently has a consensus target price of $20.40, suggesting a potential upside of 151.23%. Protagonist Therapeutics has a consensus target price of $147.13, suggesting a potential downside of 0.71%. Given BioCryst Pharmaceuticals' higher possible upside, equities analysts plainly believe BioCryst Pharmaceuticals is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89

In the previous week, BioCryst Pharmaceuticals had 6 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 18 mentions for BioCryst Pharmaceuticals and 12 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.61 beat BioCryst Pharmaceuticals' score of 0.55 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	3 Very Positive mention(s)	7 Positive mention(s)	1 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Protagonist Therapeutics beats BioCryst Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get BioCryst Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCRX vs. The Competition

Export

Metric	BioCryst Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.12B	$3.84B	$7.14B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-5.41	14.25	275.24	25.29
Price / Sales	2.37	1,473.16	656.02	98.94
Price / Cash	6.70	106.68	77.04	51.44
Price / Book	-14.25	15.12	10.33	6.20
Net Income	$263.86M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-18.47%	-4.34%	-3.32%	-2.35%
1 Month Performance	-23.32%	-0.02%	-0.41%	-2.77%
1 Year Performance	2.65%	40.64%	19.21%	7.63%

BioCryst Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCRX BioCryst Pharmaceuticals	2.4753 of 5 stars	$8.12 -2.1%	$20.40 +151.2%	+0.6%	$2.12B	$874.84M	N/A	435	News Coverage Analyst Forecast
ABVX Abivax	2.6108 of 5 stars	$114.79 flat	$156.50 +36.3%	+38.0%	$10.02B	N/A	N/A	61	News Coverage Positive News Analyst Upgrade
PRAX Praxis Precision Medicines	3.0013 of 5 stars	$351.81 flat	$585.95 +66.6%	+748.8%	$9.82B	$8.55M	N/A	110	News Coverage Positive News
KYMR Kymera Therapeutics	1.8089 of 5 stars	$117.39 flat	$128.70 +9.6%	+148.8%	$9.76B	$39.21M	N/A	170	Analyst Upgrade
IONS Ionis Pharmaceuticals	3.1981 of 5 stars	$58.09 flat	$94.20 +62.2%	-15.3%	$9.65B	$944M	N/A	1,402	Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCRX) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioCryst Pharmaceuticals (BCRX) Competitors

BCRX vs. ABVX, PRAX, KYMR, IONS, and PTGX

How does BioCryst Pharmaceuticals compare to Abivax?

Summary

How does BioCryst Pharmaceuticals compare to Praxis Precision Medicines?

Summary

How does BioCryst Pharmaceuticals compare to Kymera Therapeutics?

Summary

How does BioCryst Pharmaceuticals compare to Ionis Pharmaceuticals?

Summary

How does BioCryst Pharmaceuticals compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX vs. The Competition

BioCryst Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioCryst Pharmaceuticals (BCRX) Competitors

BCRX vs. ABVX, PRAX, KYMR, IONS, and PTGX

How does BioCryst Pharmaceuticals compare to Abivax?

Does the media prefer BCRX or ABVX?

Which has preferable valuation & earnings, BCRX or ABVX?

Do analysts prefer BCRX or ABVX?

Which has more risk & volatility, BCRX or ABVX?

Is BCRX or ABVX more profitable?

Do insiders and institutionals have more ownership in BCRX or ABVX?

Summary

How does BioCryst Pharmaceuticals compare to Praxis Precision Medicines?

Does the media favor PRAX or BCRX?

Which has preferable earnings & valuation, PRAX or BCRX?

Which has more volatility & risk, PRAX or BCRX?

Do institutionals & insiders have more ownership in PRAX or BCRX?

Is PRAX or BCRX more profitable?

Do analysts prefer PRAX or BCRX?

Summary

How does BioCryst Pharmaceuticals compare to Kymera Therapeutics?

Which has stronger valuation & earnings, KYMR or BCRX?

Do institutionals and insiders believe in KYMR or BCRX?

Is KYMR or BCRX more profitable?

Do analysts recommend KYMR or BCRX?

Which has more volatility & risk, KYMR or BCRX?

Does the media prefer KYMR or BCRX?

Summary

How does BioCryst Pharmaceuticals compare to Ionis Pharmaceuticals?

Do institutionals and insiders hold more shares of IONS or BCRX?

Which has better valuation & earnings, IONS or BCRX?

Is IONS or BCRX more profitable?

Does the media prefer IONS or BCRX?

Do analysts rate IONS or BCRX?

Which has more risk and volatility, IONS or BCRX?

Summary

How does BioCryst Pharmaceuticals compare to Protagonist Therapeutics?

Which has better valuation & earnings, BCRX or PTGX?

Which has more risk & volatility, BCRX or PTGX?

Is BCRX or PTGX more profitable?

Do analysts rate BCRX or PTGX?

Does the media refer more to BCRX or PTGX?

Do institutionals & insiders hold more shares of BCRX or PTGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX vs. The Competition

BioCryst Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools